Showing results (221-230 of 366) with videos related to

Sort By:
Pageof 37
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
Cancer Medicine|March 21, 2022
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancerBenjamin Solomon, Ana Callejo, Jair Bar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancerEnriqueta Felip, Rafael Rosell, José Antonio Maestre, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistanceJon Zugazagoitia, Ana Gómez-Rueda, Eloisa Jantus-Lewintre, et al.
The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B StudyEnriqueta Felip, Filippo G de Braud, Michela Maur, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Pageof 37